Study Summary
This is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of TC-G203 in patients with GPC3-positive recurrent or metastatic solid tumors who have progressed after prior therapies. The primary objective is to determine the maximum tolerated dose (MTD), with a secondary aim to assess preliminary clinical efficacy in solid tumors.
Want to learn more about this trial?
Request More InfoInterventions
TC-G203 cells treatmentBIOLOGICAL
TC-G203 CAR-T cells Treatment follows a lymphodepletion Drug: Fludarabine and Cyclophosphamide.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Beijing Gobroad Hospital | Beijing | Beijing Municipality | China |
| GoBroad Healthcare Group | Beijing | Beijing Municipality | China |